Audra Deveikis
Overview
Explore the profile of Audra Deveikis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gottlieb R, Clement M, Cook P, Deveikis A, Foong K, Robinson P, et al.
J Infect
. 2024 Aug;
89(4):106241.
PMID: 39182655
Background: Upregulation of IL-6 has been associated with worse prognosis in COVID-19 patients. Impact on IL-6 signalling has mostly been limited to clinical outcomes in IL-6 receptor antagonist trials. Methods:...
2.
McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J
J Pediatr
. 2010 Oct;
158(3):422-6.
PMID: 20888013
Objective: To determine the incidence of vancomycin-associated nephrotoxicity in children and to examine potential risk factors for nephrotoxicity, including average serum trough concentrations ≥ 15 mg/L. Study Design: Patients ≥...
3.
Banakar S, Thomas M, Deveikis A, Watzl J, Hayes J, Keller M
J Magn Reson Imaging
. 2008 Apr;
27(4):710-7.
PMID: 18383256
Purpose: To measure cerebral metabolites in brains of human immunodeficiency virus (HIV)-infected patients using two-dimensional (2D) proton ((1)H) magnetic resonance spectroscopy (MRS), which enables more sensitive detection of metabolites at...
4.
Pahwa S, Muresan P, Sleasman J, Fenton T, Moye J, Deveikis A, et al.
J Allergy Clin Immunol
. 2007 Apr;
119(6):1538-41.
PMID: 17418382
No abstract available.
5.
Starr S, McFarland E, Muresan P, Fenton T, Pitt J, Douglas S, et al.
AIDS
. 2003 Oct;
17(15):2181-9.
PMID: 14523275
Objectives: To define the tolerated dose of recombinant interleukin-2 (rIL-2) in HIV-infected children (part A), and to determine the safety and immunologic effects of the tolerated rIL-2 dose in a...